Loading...
MEK inhibition increases lapatinib sensitivity via modulation of FOXM1
The standard targeted therapy for HER2-overexpressing breast cancer is the HER2 monoclonal antibody, trastuzumab. Although effective, many patients eventually develop trastuzumab resistance. The dual EGFR/HER2 small molecule tyrosine kinase inhibitor lapatinib is approved for use in trastuzumab-refr...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3650616/ https://ncbi.nlm.nih.gov/pubmed/23531216 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|